{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', \"SIGNATURE OF SPONSOR'S RESPONSIBLE OFFICERS\", '(Scientific/Medical Monitor, Regulatory Representative, Clinical Study Team Lead, and', 'Biostatistician)', 'To the best of my knowledge, this document accurately describes the conduct of the study.', 'Study Title:', 'An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810', \"versus Investigator's Choice of Chemotherapy in Recurrent or\", 'Metastatic Cervical Carcinoma', 'Protocol Number:', 'R2810-ONC-1676/GOG-3016 (CVP1601) ENGOT-cx9', 'Protocol Version:', 'R2810-ONC-1676/GOG-3016 (CVP1601) ENGOT cx9', 'Amendment 7', 'See appended electronic signature page', \"Sponsor's Responsible Scientific/Medical Monitor\", 'See appended electronic signature page', \"Sponsor's Responsible Regulatory Representative\", 'See appended electronic signature page', \"Sponsor's Responsible Clinical Study Team Lead\", 'See appended electronic signature page', \"Sponsor's Responsible Biostatistician\", 'Regeneron Pharmaceuticals, Inc.', 'Page 145 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Signature Page for VV-RIM-00146791 v1.0', 'ESig Approval', '600', 'ESig Approval', '21 14:14:43 GMT+0000', 'ESig Approval', 'I-2021 14:35:22 GMT+0000', 'ESig Approval', '-2021 14:46:23 GMT+0000', 'ESig Approval', '2021 16:10:37 GMT+0000', 'Signature Page for VV-RIM-00146791 v1.0 Approved', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}